LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 11

Search options

  1. Article ; Online: A Review of Hydrogen Sensors for ECLSS

    Chenghao Jia / Ling Zhao / Gang Huang / Litao Liu / Weirong Wang / Yunkai Yang / Yang Miao

    Applied Sciences, Vol 13, Iss 6869, p

    Fundamentals, Recent Advances, and Challenges

    2023  Volume 6869

    Abstract: The development of hydrogen sensors with high detection accuracy, fast response times, long calibration periods, and good stability has become the focus of the space station environmental control and life support subsystem. We analyze the current ... ...

    Abstract The development of hydrogen sensors with high detection accuracy, fast response times, long calibration periods, and good stability has become the focus of the space station environmental control and life support subsystem. We analyze the current research status of different types of hydrogen sensors, including catalyst combustion type, heat conduction type, semiconductor type, fiber optic type, etc. The response signals of most hydrogen sensors are affected by temperature and humidity, resulting in cross-sensitivity. Reducing the cross-sensitivity of temperature, humidity, and other interfering factors to achieve accurate hydrogen measurement in different environments is a challenge that limits the development of hydrogen sensors. Several hydrogen sensors that are currently commercially available have a narrow operating temperature range, most of them can only measure at room temperature, and high-temperature environments require a higher accuracy and lifetime of the sensor than required at room temperature. Many new hydrogen-sensitive materials were developed to improve the performance of the sensors. The excellent performance of fiber-optic hydrogen sensors is beneficial to temperature compensation and distributed multiparameter measurement, as well as to the research and development of intelligent sensing systems, in the context of the Internet of Things. The signal detection and demodulation techniques of fiber-optic sensors are the focus of future hydrogen sensor research.
    Keywords hydrogen energy ; sensor ; sensitive materials ; detecting technology ; Technology ; T ; Engineering (General). Civil engineering (General) ; TA1-2040 ; Biology (General) ; QH301-705.5 ; Physics ; QC1-999 ; Chemistry ; QD1-999
    Subject code 621
    Language English
    Publishing date 2023-06-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Sarcopenia as an important determinant for adverse outcomes in patients with pyogenic liver abscess

    Li Liu / Shaohua Liu / Meng Hao / Song Hu / Tian Yu / Yunkai Yang / Zhelong Liu

    PeerJ, Vol 11, p e

    2023  Volume 16055

    Abstract: Background Low muscle mass/sarcopenia has been associated with poor prognosis in many diseases, but its clinical significance in pyogenic liver abscess (PLA) remains unclear. The purpose of this study is to investigate the relationship between muscle ... ...

    Abstract Background Low muscle mass/sarcopenia has been associated with poor prognosis in many diseases, but its clinical significance in pyogenic liver abscess (PLA) remains unclear. The purpose of this study is to investigate the relationship between muscle mass and prognosis of patients with PLA. Methods A total of 154 adult patients with PLA hospitalized at Tongji Hospital (Wuhan, Hubei, China) between October 2011 and June 2021 were included in this retrospective analysis. Muscle-fat related indicators were measured by computed tomography (CT) images at the third lumbar vertebra (L3) level. The data of patients between the sarcopenia group and non-sarcopenia group were compared. Multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were performed. Results The skeletal muscle index (SMI) was independently associated with adverse outcomes (95% CI [0.649–0.954], P = 0.015) of PLA in multivariate logistic regression analysis. This conclusion held true in sex-specific subgroup analysis. ROC analysis indicated that SMI may predict adverse outcomes in both male (area under the ROC curve [AUC], 0.718; cut-off, 52.59; P < 0.001) and female (AUC, 0.714; cut-off, 38.39; P = 0.017) patient populations. Conclusions Sarcopenia serves as an independent risk factor for poor prognosis in PLA and patients with sarcopenia may be more prone to adverse outcomes.
    Keywords Pyogenic liver abscess ; Sarcopenia ; Muscle mass ; Body composition ; Prognosis ; Retrospective ; Medicine ; R ; Biology (General) ; QH301-705.5
    Subject code 610
    Language English
    Publishing date 2023-10-01T00:00:00Z
    Publisher PeerJ Inc.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Notch signaling pathway

    Binghan Zhou / Wanling Lin / Yaling Long / Yunkai Yang / Huan Zhang / Kongming Wu / Qian Chu

    Signal Transduction and Targeted Therapy, Vol 7, Iss 1, Pp 1-

    architecture, disease, and therapeutics

    2022  Volume 33

    Abstract: Abstract The NOTCH gene was identified approximately 110 years ago. Classical studies have revealed that NOTCH signaling is an evolutionarily conserved pathway. NOTCH receptors undergo three cleavages and translocate into the nucleus to regulate the ... ...

    Abstract Abstract The NOTCH gene was identified approximately 110 years ago. Classical studies have revealed that NOTCH signaling is an evolutionarily conserved pathway. NOTCH receptors undergo three cleavages and translocate into the nucleus to regulate the transcription of target genes. NOTCH signaling deeply participates in the development and homeostasis of multiple tissues and organs, the aberration of which results in cancerous and noncancerous diseases. However, recent studies indicate that the outcomes of NOTCH signaling are changeable and highly dependent on context. In terms of cancers, NOTCH signaling can both promote and inhibit tumor development in various types of cancer. The overall performance of NOTCH-targeted therapies in clinical trials has failed to meet expectations. Additionally, NOTCH mutation has been proposed as a predictive biomarker for immune checkpoint blockade therapy in many cancers. Collectively, the NOTCH pathway needs to be integrally assessed with new perspectives to inspire discoveries and applications. In this review, we focus on both classical and the latest findings related to NOTCH signaling to illustrate the history, architecture, regulatory mechanisms, contributions to physiological development, related diseases, and therapeutic applications of the NOTCH pathway. The contributions of NOTCH signaling to the tumor immune microenvironment and cancer immunotherapy are also highlighted. We hope this review will help not only beginners but also experts to systematically and thoroughly understand the NOTCH signaling pathway.
    Keywords Medicine ; R ; Biology (General) ; QH301-705.5
    Subject code 570
    Language English
    Publishing date 2022-03-01T00:00:00Z
    Publisher Nature Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Feasibility of using chest computed tomography (CT) imaging at the first lumbar vertebra (L1) level to assess skeletal muscle mass

    Shaohua Liu / Xia Han / Jianjun Li / Xia Xie / Yunkai Yang / Wangyan Jiang / Li Liu / Zhelong Liu

    PeerJ, Vol 11, p e

    a retrospective study

    2023  Volume 16652

    Abstract: Background Skeletal muscle mass is an essential parameter for diagnosing sarcopenia. The gold standard for assessing skeletal muscle mass is using computed tomography (CT) to measure skeletal muscle area at the third lumbar vertebra (L3) level. This ... ...

    Abstract Background Skeletal muscle mass is an essential parameter for diagnosing sarcopenia. The gold standard for assessing skeletal muscle mass is using computed tomography (CT) to measure skeletal muscle area at the third lumbar vertebra (L3) level. This study aims to investigate whether skeletal muscle mass could be evaluated at the first lumbar vertebra (L1) level using images obtained from routine chest CT scans. Methods Skeletal muscle index (SMI, cm2/m2) and skeletal muscle density (SMD, HU) are commonly used to measure relative muscle mass and the degree of fat infiltration. This study used CT images at the L1 level to measure the skeletal muscle area (SMA, cm2) in 815 subjects from the health examination center. Linear regression analysis was used to explore the association between L1 and L3 measurements. The receiver operating characteristic (ROC) analysis was used to assess the predictive performance of L1 SMI for sarcopenia. The sex-specific cut-off values for low skeletal muscle mass in patients under the age of 60 were determined using the following formula: “mean − 1.28 × standard deviation.” A multivariate linear regression model was established. Results A significantly higher SMI at the L1 level was found in males than in females (43.88 ± 6.33 cm2/m2 vs 33.68 ± 5.03 cm2/m2; P < 0.001). There were strong correlations between measures at the L1 and L3 levels in both the total subject and sex-specific analyses. A negative association was found between age and L3 SMI in males (r = −0.231, P = 0.038). Both body mass index (BMI) and body surface area (BSA) were positively associated with L1 SMI in both males and females. A multivariate analysis was used to establish a prediction rule to predict SMI at the L3 level. The assessment of consistency and interchangeability between predicted and actual SMI at the L3 level yielded moderately good results. Considering the significant differences observed between male and female participants, the sex-specific cut-off values of the L1 SMI for defining low skeletal ...
    Keywords Sarcopenia ; Skeletal muscle mass ; Computed tomography ; The first lumbar vertebra ; Medicine ; R ; Biology (General) ; QH301-705.5
    Subject code 796
    Language English
    Publishing date 2023-12-01T00:00:00Z
    Publisher PeerJ Inc.
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus

    Yuntao Zhang / Haiping Chen / Jun Lv / Tao Huang / Ruizhi Zhang / Dongjuan Zhang / Linyun Luo / Sheng Wei / Xiaoqin Liu / Shangxiao Zhang / Qiuyue Mu / Rongdong Huang / Jiao Huang / Yanhui Xiao / Yunkai Yang / Yuting Han / Hao Gong / Qinghu Guan / Fangqin Xie /
    Hui Wang / Liming Li / Xiaoming Yang

    Vaccines, Vol 10, Iss 1020, p

    2022  Volume 1020

    Abstract: Background: To evaluate the immunogenicity and safety of the COVID-19 vaccine (Vero cell), inactivated, in a population aged ≥60 years with hypertension or(/and) diabetes mellitus. Methods: A total of 1440 participants were enrolled and divided into four ...

    Abstract Background: To evaluate the immunogenicity and safety of the COVID-19 vaccine (Vero cell), inactivated, in a population aged ≥60 years with hypertension or(/and) diabetes mellitus. Methods: A total of 1440 participants were enrolled and divided into four groups, 330 in the hypertension group, 330 in the diabetes group, 300 in the hypertensive combined with diabetes group (combined disease group), and 480 in the healthy population group. Two doses of the COVID-19 vaccine (Vero cell), inactivated, were administered at a 21-day interval and blood samples were collected before vaccination and 28 days after the second dose to evaluate the immunogenicity. The adverse events and changes in blood pressure and blood glucose levels after vaccination were recorded. Results: The seroconversion rate of the COVID-19 neutralizing antibodies was 100% for all participants. The post-inoculation geometric mean titer (GMT) in the four groups of the hypertension, diabetes, combined disease, and healthy populations were 73.41, 69.93, 73.84, and 74.86, respectively. The seroconversion rates and post-vaccination GMT in the hypertension, diabetes, and combined disease groups were non-inferior to the healthy population group. The rates of vaccine-related adverse reactions were 11.93%, 14.29%, 12.50%, and 9.38%, respectively. No serious adverse events were reported during the study. No apparent abnormal fluctuations in blood pressure and blood glucose values were observed after vaccination in participants with hypertension or(/and) diabetes. Conclusions: The COVID-19 vaccine (Vero cell), inactivated, showed good immunogenicity and safety in patients aged ≥60 years suffering from hypertension or(/and) diabetes mellitus.
    Keywords COVID-19 vaccine (Vero cell) ; inactivated ; elderly hypertensive population ; elderly diabetic population ; safety ; immunogenicity ; Medicine ; R
    Subject code 630
    Language English
    Publishing date 2022-06-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article: Improving benefit-cost analysis to overcome financing difficulties in promoting energy-efficient renovation of existing residential buildings in China

    Wang, Xiaotong / Bo Zhou / Jinlong Ouyang / Meijun Lu / Wei Mao / Yunkai Yang

    Applied energy. 2015 Mar. 01, v. 141

    2015  

    Abstract: Energy-efficient renovation of existing residential buildings is an important energy policy in China, but financing difficulties seriously hinder the promotion of the policy. In this article, novel indices based on benefit-cost analysis are presented to ... ...

    Abstract Energy-efficient renovation of existing residential buildings is an important energy policy in China, but financing difficulties seriously hinder the promotion of the policy. In this article, novel indices based on benefit-cost analysis are presented to overcome the barriers. Firstly, benefit-cost analysis is expanded to include the ratio of energy-saving benefit to investment cost (EnIR), the ratio of environmental benefit to investment cost (EvIR), and the ratio of economic benefit to investment cost (EcIR). The above ratios are applied to determine the optimum plans with the highest cost-effectiveness for the buildings to be renovated. Secondly, according to the actual situation regarding both the government and residents, EnIR is modified to the ratio of energy-saving benefit from the retrofit plan to the part of the investment cost undertaken by the government (EnIgR), EvIR to the ratio of environmental benefit from the retrofit plan to the part of the investment cost undertaken by the government (EvIgR), and EcIR to the ratio of economic benefit from the retrofit plan to the part of the investment cost undertaken by residents (EcIrR). The modified ratios can increase awareness of residents in respect of their individual benefits from the adoption of the optimum plans, and can attract them to co-invest. Through these two steps, financing difficulties could be eased or even no longer considered as obstacles to some extent. The ratios are applied to a case study building in Hangzhou. Based on the results, a “win–win” model, consistent with market principles, is developed, in which both the government and residents can co-invest and co-benefit. The model has proven to be an effective decision-making tool in promoting the building renovation policy in China.
    Keywords buildings ; case studies ; cost benefit analysis ; cost effectiveness ; decision support systems ; energy conservation ; energy efficiency ; energy policy ; funding ; markets ; models ; residential housing ; China
    Language English
    Dates of publication 2015-0301
    Size p. 119-130.
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 2000772-3
    ISSN 0306-2619
    ISSN 0306-2619
    DOI 10.1016/j.apenergy.2014.12.001
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  7. Article: Peptide TQS169 prevents osteoporosis in rats by enhancing osteogenic differentiation and calcium absorption

    Wang, Huan / Huiyu Li / Li Ye / Meiqing Feng / Nanye Chen / Shuru Shen / Wei Zhou / Xiangxiang Hu / Xiaochen Yu / Yunkai Yang

    Journal of functional foods. 2018 Oct., v. 49

    2018  

    Abstract: The preventive effects of TQS169 peptide on osteoporosis were investigated and the mechanisms of promoting osteogenic differentiation and calcium absorption were also studied in vitro and vivo in this research. Wistar rats were given a low-Calcium diet ... ...

    Abstract The preventive effects of TQS169 peptide on osteoporosis were investigated and the mechanisms of promoting osteogenic differentiation and calcium absorption were also studied in vitro and vivo in this research. Wistar rats were given a low-Calcium diet treated with different doses of peptide TQS169 and extra CaCl2 for 4 weeks. The content of Calcium, OPG in serum and the Ca content of the femur were increased in high-dose-treated rats. The osteoporosis model induced by retinoic acid was established to measure the related factors. High dosage of TQS169 treated group showed the protective effects. Osteoblastogenesis differentiation of MC3T3-E1 cells treated with TQS169 were accelerated through improving ALP activity, promoting mineral matrix formation and the expression of typical genes of RUNX2, OCN and COL I. Taking all the experiments together, our study confirms the protective effects of TQS169 on osteoporosis and explains the potential mechanism for the first time.
    Keywords blood serum ; bone formation ; calcium ; calcium chloride ; diet ; femur ; genes ; intestinal absorption ; laboratory animals ; models ; osteoporosis ; protective effect ; rats ; retinoic acid
    Language English
    Dates of publication 2018-10
    Size p. 113-121.
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 2511964-3
    ISSN 1756-4646
    ISSN 1756-4646
    DOI 10.1016/j.jff.2018.08.021
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  8. Article: Live Streptococcus suis type 5 strain XS045 provides cross-protection against infection by strains of types 2 and 9

    Jiang, Xiaowu / Hongxia Shen / Jiusheng Wu / Lexin Zhu / Weihuan Fang / Xiaoliang Li / Ying Shan / Yuanxing Gu / Yunkai Yang

    Vaccine. 2016 Dec. 12, v. 34, no. 51

    2016  

    Abstract: Streptococcus suis is one of the common pathogens causing diseases in pigs and covers 35 serotypes with the type 2 strains being more pathogenic and zoonotic. Existing inactivated or subunit vaccines, in clinical use or under trial, could not provide ... ...

    Abstract Streptococcus suis is one of the common pathogens causing diseases in pigs and covers 35 serotypes with the type 2 strains being more pathogenic and zoonotic. Existing inactivated or subunit vaccines, in clinical use or under trial, could not provide cross protection against other serotypes. We identified a natural low-virulence S. suis type 5 strain XS045 as a live vaccine candidate because it is highly adhesive to the cultured HEp-2 cells, but with no apparent pathogenicity in mice and piglets. We further demonstrate that subcutaneous administration of the live XS045 strain to mice induced high antibody responses and was able to provide cross protection against challenges by a type 2 strain HA9801 (100% protection) and a type 9 strain JX13 (85% protection). Induction of high-titer antibodies with opsonizing activity as well as their cross-reactivity to surface proteins of the types 2 and 9 strains and anti-adhesion effect could be the mechanisms of cross protection. This is the first report that a live vaccine candidate S. suis type 5 strain could induce cross-protection against strains of types 2 and 9. This candidate strain is to be further examined for safety in pigs of different ages and breeds as well as for its protection against other serotypes or other strains of the type 2, a serotype of particular importance from public health concern.
    Keywords antibodies ; breeds ; cross immunity ; cross reaction ; human cell lines ; live vaccines ; mice ; pathogenicity ; pathogens ; piglets ; public health ; serotypes ; Streptococcus suis ; subcutaneous injection ; subunit vaccines ; surface proteins
    Language English
    Dates of publication 2016-1212
    Size p. 6529-6538.
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2016.05.003
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  9. Article ; Online: The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates

    Nawal Al Kaabi / Abderrahim Oulhaj / Farida Ismail Al Hosani / Shamma Al Mazrouei / Omer Najim / Salah Eldin Hussein / Jehad Saleh Abdalla / Mohammed Saifuddin Fasihuddin / Afnan Abdellatif Hassan / Gehad Elghazali / Ahmed Al Rumaithi / Jumana Al Azazi / Stefan Weber / Rami Beiram / Khatija A. Parekh / Mohamud Sheek-Hussein / Yunkai Yang / Yang Xiaoming / Jenny Quliang /
    Islam Eltantawy / Sally Mahmoud / Ashish Koshy / Peng Xiao / Subhashini Ganesan / Wael Elamin / Walid Zaher

    Scientific Reports, Vol 12, Iss 1, Pp 1-

    2022  Volume 8

    Abstract: Abstract Based on the findings from the Phase III clinical trials of inactivated SARS COV-2 Vaccine, (BBIBP-CORV) emergency use authorization (EUA) was granted for the vaccine to frontline workers in the UAE. A prospective cohort study was conducted ... ...

    Abstract Abstract Based on the findings from the Phase III clinical trials of inactivated SARS COV-2 Vaccine, (BBIBP-CORV) emergency use authorization (EUA) was granted for the vaccine to frontline workers in the UAE. A prospective cohort study was conducted among frontline workers to estimate the incidence rate and risk of symptomatic COVID-19 infection 14 days after the second dose of inoculation with BBIBP-CORV inactivated vaccine. Those who received two doses of the BBIBP-CORV vaccine in the period from 14th of September 2020 (first dose) to 21st of December 2020 (second dose) were followed up for COVID-19 infections. 11,322 individuals who received the two-dose BBIBP-CORV vaccine were included and were followed up post the second dose plus fourteen days. The incidence rate of symptomatic infection was 0.08 per 1000-person days (95% CI 0.07, 0.10). The estimated absolute risk of developing symptomatic infection was 0.97% (95% CI 0.77%, 1.17%). The confirmed seroconversion rate was 92.8%. There were no serious adverse events reported and no individuals suffered from severe disease. Our findings show that vaccinated individuals are likely to remain protected against symptomatic infection or becoming PCR positive for SARS COV 2 following the second dose of the vaccination.
    Keywords Medicine ; R ; Science ; Q
    Subject code 610 ; 630
    Language English
    Publishing date 2022-01-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older

    Wanshen Guo / Kai Duan / Yuntao Zhang / Zhiming Yuan / Yan-Bo Zhang / Zejun Wang / Dongyang Zhao / Huajun Zhang / Zhiqiang Xie / Xinguo Li / Cheng Peng / Wei Zhang / Yunkai Yang / Wei Chen / Xiaoxiao Gao / Wangyang You / Xue-Wei Wang / Zhengli Shi / Yanxia Wang /
    Xu-Qin Yang / Lianghao Zhang / Lili Huang / Qian Wang / Jia Lu / Yong-Li Yang / Jing Guo / Wei Zhou / Xin Wan / Cong Wu / Wenhui Wang / Jianhui Du / Xuanxuan Nian / Xing-Hang Li / Shihe Huang / Shuo Shen / Shengli Xia / An Pan / Xiaoming Yang

    EClinicalMedicine, Vol 38, Iss , Pp 101010- (2021)

    A randomized, double-blind, placebo-controlled, phase 1/2 trial

    2021  

    Abstract: Background: We aimed to assess the safety and immunogenicity of an inactivated vaccine against COVID-19 in Chinese adults aged ≥18 years. Methods: This is an ongoing randomized, double-blind, placebo-controlled, phase 1/2 clinical trial among healthy ... ...

    Abstract Background: We aimed to assess the safety and immunogenicity of an inactivated vaccine against COVID-19 in Chinese adults aged ≥18 years. Methods: This is an ongoing randomized, double-blind, placebo-controlled, phase 1/2 clinical trial among healthy adults aged ≥18 years in Henan Province, China. Participants (n = 336 in 18–59 age group and n = 336 in ≥60 age group) were enrolled between April 12 and May 17 2020, and were equally randomized to receive vaccine or placebo (aluminum hydroxide adjuvant) in a three-dose schedule of 2·5, 5, or 10 µg on days 0, 28, and 56. Another 448 adults aged 18–59 years were equally allocated to four groups (a one-dose schedule of 10 µg, and two-dose schedules of 5 µg on days 0 and 14/21/28) and received vaccine or placebo (ratio 3:1 within each group). The primary outcomes were 7-day post-injection adverse reactions and neutralizing antibody titres on days 28 and 90 after the whole-course vaccination. Trial registration: www.chictr.org.cn #ChiCTR2000031809. Findings: The 7-day adverse reactions occurred in 4·8% to 32·1% of the participants in various groups, and most adverse reactions were mild, transient, and self-limiting. Twenty participants reported 68 serious adverse events which were judged to be unrelated to the vaccine. The 90-day post-injection geometric mean titres of neutralizing antibody ranged between 87 (95% CI: 61–125) and 129 (99–169) for three-dose schedule among younger and older adults; 20 (14–27), 53 (38–75), and 44 (32–61) in 5 µg days 0 and 14/21/28 groups, respectively, and 7 (6–9) in one-dose 10 µg group. There were no detectable antibody responses in all placebo groups. Interpretation: The inactivated vaccine against COVID-19 was well tolerated and immunogenic in both younger and older adults. The two-dose schedule of 5 µg on days 0 and 21/28 and three-dose schedules on days 0, 28, and 56 could be further evaluated for long-term safety and efficacy in the phase 3 trials.
    Keywords Medicine (General) ; R5-920
    Subject code 630
    Language English
    Publishing date 2021-08-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top